Business

Hi-Tech Pharmacal has reported a 10% increase in net sales of generic products for the quarter ended April 30, 2012 compared to the same quarter in 2011, an increase due primarily to a sales increase… Read more . . .

Renaissance Acquisition Holdings has acquired Texas-based CDMO DPT Laboratories, which offers MDI and nasal spray testing and manufacturing. DPT has facilities in San Antonio, TX and Lakewood, NJ. According to the company, the management team… Read more . . .

Prosonix and Imperial College London have signed an agreement to collaborate on development of inhaled therapies based on multi-component particles (MCPs) manufactured using Prosonix’s proprietary particle engineering technology. The company will coordinate with Dr. Omar… Read more . . .

According to Insmed Incorporated, the company has entered into a loan agreement with Hercules Technology Growth Capital that will allow it to access up to $20 million for continued development of Arikace inhaled liposomal amikacin.… Read more . . .

GlaxoSmithKline has acquired rights to several inhaled drug candidates manufactured using Liquidia Technologies’ PRINT (Particle Replication In Non-Wetting Templates) platform. The PRINT nanofabrication technology produces particles with narrow size distribution and any desired shape. According… Read more . . .

Particle design and dry powder inhalation specialist Hovione has announced that sales for the fiscal year that ended in March, 2012 increased to $180 million,a 24% increase over the previous year. In addition to inhalation… Read more . . .

MicroDose Therapeutx and Moerae Matrix have agreed to collaborate on development of a dry powder inhaler, using MicroDose DPI technology to deliver Moerae’s MMI-0100 MK2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). There… Read more . . .

According to Bloomberg News, Merck plans to appeal a ruling by Judge Peter Sheridan of the US District Court for the District of New Jersey that Merck failed to prove its allegation that Apotex infringed… Read more . . .

Rigel Pharmaceuticals has granted AstraZeneca an exclusive worldwide license for development and commercialization of its R256 inhaled JAK inhibitor for the treatment for moderate to severe asthma. The deal includes an upfront payment of $1… Read more . . .

A new report from Transparency Market Research titled “Asthma and COPD Drug Market – Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 – 2017” predicts an increase in the asthma and COPD… Read more . . .